North America Antibody-Drug Conjugates Market - Forecasts from 2019 to 2024
The North America antibody-drug conjugates (ADCs) market is expected to reach a market size of $5,619.220 million by 2024 with a CAGR of 27.33%. The market is propelled to grow during the forecast period owing to the extensive research which is being carried out by the big companies situated in this region to find an effective cure for several malignancies, haematological and non-haematological. The growing health expenditure is further contributing to the market growth in the forecast period with the United States having the highest health expenditure among the developed regions of the world. Additionally, with the shift towards the value-based care is further providing an opportunity for the market to grow due to the continuous efforts which are being taken for the development of the targeted drug therapies especially in the case of cancer. ADCs are considered as a part of the specialized subset of highly potent APIs, hence with the growing drug API industry, the market will continue to thrive during the forecast period and in the upcoming years.
The North America antibody-drug conjugates market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target, by indication, and by country.
The North America antibody-drug conjugates market on segmented based on target, indication, and country. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.
Country-wise analysis has been provided with detailed analysis and forecast for the period 2018 to 2024, taking 2018 as the base year. The regional market has been broken down into USA, Canada, and Mexico. A thorough analysis and forecast have been done along with the prevailing market trends and opportunities which each of these countries presents for the manufacturers.
Major players in the North America antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the North America antibody-drug conjugates market.
Segmentation
The North America antibody-drug conjugates market has been analyzed through the following segments:
The North America antibody-drug conjugates market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target, by indication, and by country.
The North America antibody-drug conjugates market on segmented based on target, indication, and country. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.
Country-wise analysis has been provided with detailed analysis and forecast for the period 2018 to 2024, taking 2018 as the base year. The regional market has been broken down into USA, Canada, and Mexico. A thorough analysis and forecast have been done along with the prevailing market trends and opportunities which each of these countries presents for the manufacturers.
Major players in the North America antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the North America antibody-drug conjugates market.
Segmentation
The North America antibody-drug conjugates market has been analyzed through the following segments:
- By Target
- CD 30
- CD 22
- HER 2
- By Indication
- Haematologic Malignancies
- Non-Haematologic Malignancies
- By Country
- USA
- Canada
- Mexico
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET BY TARGET
5.1. CD
5.2. CD
5.3. HER
6. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION
6.1. Haematologic Malignancies
6.2. Non Haematologic Malignancies
7. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET BY COUNTRY
7.1. USA
7.2. Canada
7.3. Mexico
8. COMPETITIVE INTELLIGENCE
8.1. Market Positioning Matrix and Ranking
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. F. Hoffmann-La Roche Ltd.
9.2. Pfizer Inc.
9.3. Synthon Holding B.V.
9.4. Immunomedics
9.5. Astellas Pharma Inc.
9.6. Seattle Genetics, Inc.
9.7. Takeda Pharmaceutical Company Limited
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET BY TARGET
5.1. CD
5.2. CD
5.3. HER
6. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION
6.1. Haematologic Malignancies
6.2. Non Haematologic Malignancies
7. NORTH AMERICA ANTIBODY-DRUG CONJUGATES MARKET BY COUNTRY
7.1. USA
7.2. Canada
7.3. Mexico
8. COMPETITIVE INTELLIGENCE
8.1. Market Positioning Matrix and Ranking
8.2. Recent Investments and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. F. Hoffmann-La Roche Ltd.
9.2. Pfizer Inc.
9.3. Synthon Holding B.V.
9.4. Immunomedics
9.5. Astellas Pharma Inc.
9.6. Seattle Genetics, Inc.
9.7. Takeda Pharmaceutical Company Limited
